We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > oophoroma

News List

Pfizer, Merck KGaA's Bavencio flunks ovarian cancer trial fiercepharma
November 26, 2018
Monday, the drugmakers reported that their immuno-oncology drug had failed a phase 3 trial in previously treated ovarian cancer patients, failing to stave off cancer progression or prolong life either on its own or in tandem with chemo.
Merck and Pfizer chalk up another fail for Bavencio pharmaphorum
November 21, 2018
Merck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in ovarian cancer, denting their hopes of building momentum for the product.
Merck KGaA and Pfizer's Bavencio falls short in ovarian cancer pharmafile
November 21, 2018
Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, whether as a monotherapy or in combination with chemotherapy.
Pfizer, Merck KGaA's Bavencio flunks ovarian cancer trial fiercepharma
November 20, 2018
Mark another tally for Pfizer and Merck KGaA’s Bavencio in the “loss” column.